

DIASORIN LAUNCHES THE FIRST FULLY AUTOMATED TEST FOR ADENOVIRUS GASTRO-INTESTINAL INFECTION

The virus is, together with Rotavirus, the first gastro-intestinal infection in terms of volumes tested in the world. In Europe, about 5.5 million tests are performed every year and the market is estimated to be over 9 million euro.

September 18, 2014 - Saluggia (VC) - **DiaSorin** (FTSE Mid Cap:DIA) launched, in markets outside the United States and the United Kingdom, its sixth **LIAISON** test for the **qualitative detection of Adenovirus** in stool samples. The test is an addition to the 5 most important tests of the "stool testing" panel, already available on the market (C. Difficile toxin A&B, C. Difficile GDH, Helicobacter Pylori, EHEC, Rotavirus).

Adenovirus - a virus that is resistant to drugs and dangerous for infants, children and immunosuppressed patients - is, along with Rotavirus, extremely spread-out worldwide and is the first gastro-intestinal infection in terms of volumes tested: in Europe alone, about 5.5 million tests are made every year for a market that is estimated at more than € 9 million. Throughout the world, the Adenovirus test is usually done in conjunction with that for Rotavirus (combo test "Rota / Adeno").

Chen Even, Senior Corporate Vice President Commercial Operations of DiaSorin, commented: *"With the launch of Adenovirus, DiaSorin increases its panel of specific tests of gastro-intestinal infections on stool samples, thus offering a panel of 6 automated diagnostic solutions. Furthermore, since Adenovirus is always tested together with Rotavirus, it is possible to propose both tests together, providing a complete solution to a new customer base, which today still uses manual techniques that are often problematic."*

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	LIAISON Adenovirus		
Diagnosis	Qualitative determination of Adenovirus in Stool samples		
Business segment	Immunodiagnosics	✓	Molecular Diagnostics
Potential market	€ 9 mln in Europe		
Technology	CLIA	✓	Extraction
	ELISA		Amplification/Detection
	RIA		HLA Typing
Clinical Area	Infectious Disease		Infectious Disease
	Hepatitis and Retroviruses		
	Oncology & Endocrinology		Onco-hematology
	Bone & Mineral		
	Cardiac Markers		
	GI Stool Testing	✓	

About DiaSorin

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava

Investor Relations & Corporate Communication Director
 Tel: +39.0161.487988
riccardo.fava@diasorin.it

Margherita Sacerdoti

Investor Relations Specialist
 Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it